In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q ...
SMA is a rare, genetic neuromuscular condition that affects people across age groups. With treatment landscapes evolving ...
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment ...
Biogen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...
Biogen (BIIB) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a ...
The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age, and could free them from having to take regular, lifelong SMA treatments ...
Biogen Inc (BIIB) stock reached a 52-week high of 177.37 USD, marking a significant milestone for the biotechnology company. This peak reflects an 11.02% increase in its stock price over the past year ...
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative ...
Pharmaceutical Technology on MSN
High-dose Spinraza inches closer to EU approval despite FDA setback
A CHMP panel has recommended the high-dose version’s approval, countering an FDA rejection for the drug in recent months.
Treatment Market is projected to grow at a healthy rate of around 13% by 2026. This growth is primarily driven by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback